Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder

Malgorzata MacIukiewicz, Victoria S. Marshe, Arun K. Tiwari, Trehani M. Fonseka, Natalie Freeman, Susan Rotzinger, Jane A. Foster, James L. Kennedy, Sidney H. Kennedy, Daniel J. Müller

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Aim: This study investigated polymorphisms of five inflammatory-related genes for association with duloxetine and placebo response in patients with major depression. Patients & methods: Twenty SNPs in IL-1β, IL-2, IL-6, TSPO and BDNF were genotyped in major depressive disorder patients treated with either duloxetine (n = 215) or placebo (n = 235) for up to 8 weeks. Treatment response was measured with the Montgomery-Åsberg Depression Rating Scale. Results: IL-6 variants rs2066992 and rs10242595 were nominally associated with response to duloxetine (p = 0.047 and p = 0.028, respectively). Notably, the variant rs2066992 was also associated with placebo response (p = 0.026). However, none of our results remained significant after correction for multiple testing. Conclusion: Our findings tentatively suggest that IL-6 variants play a role in duloxetine and placebo response, which warrants further investigation.

Original languageEnglish (US)
Pages (from-to)1919-1929
Number of pages11
JournalPharmacogenomics
Volume16
Issue number17
DOIs
StatePublished - Nov 2015
Externally publishedYes

Keywords

  • BDNF
  • cytokines
  • depression
  • duloxetine
  • IL-6
  • inflammation
  • placebo
  • treatment response
  • TSPO

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Fingerprint

Dive into the research topics of 'Genetic variation in IL-1β, IL-2, IL-6, TSPO and BDNF and response to duloxetine or placebo treatment in major depressive disorder'. Together they form a unique fingerprint.

Cite this